BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22428059)

  • 1. Differential expression of Vegfr-2 and its soluble form in preeclampsia.
    Munaut C; Lorquet S; Pequeux C; Coulon C; Le Goarant J; Chantraine F; Noël A; Goffin F; Tsatsaris V; Subtil D; Foidart JM
    PLoS One; 2012; 7(3):e33475. PubMed ID: 22428059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.
    Soto E; Romero R; Kusanovic JP; Ogge G; Hussein Y; Yeo L; Hassan SS; Kim CJ; Chaiworapongsa T
    J Matern Fetal Neonatal Med; 2012 May; 25(5):498-507. PubMed ID: 21867402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.
    Erez O; Romero R; Espinoza J; Fu W; Todem D; Kusanovic JP; Gotsch F; Edwin S; Nien JK; Chaiworapongsa T; Mittal P; Mazaki-Tovi S; Than NG; Gomez R; Hassan SS
    J Matern Fetal Neonatal Med; 2008 May; 21(5):279-87. PubMed ID: 18446652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.
    Chaiworapongsa T; Romero R; Savasan ZA; Kusanovic JP; Ogge G; Soto E; Dong Z; Tarca A; Gaurav B; Hassan SS
    J Matern Fetal Neonatal Med; 2011 Oct; 24(10):1187-207. PubMed ID: 21827221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies.
    Gu Y; Lewis DF; Wang Y
    J Clin Endocrinol Metab; 2008 Jan; 93(1):260-6. PubMed ID: 17956952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma.
    Chaiworapongsa T; Romero R; Gotsch F; Kusanovic JP; Mittal P; Kim SK; Erez O; Vaisbuch E; Mazaki-Tovi S; Kim CJ; Dong Z; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2010 Feb; 23(2):167-78. PubMed ID: 20213923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
    Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast.
    Munaut C; Lorquet S; Pequeux C; Blacher S; Berndt S; Frankenne F; Foidart JM
    Hum Reprod; 2008 Jun; 23(6):1407-15. PubMed ID: 18413304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.
    Chaiworapongsa T; Romero R; Korzeniewski SJ; Cortez JM; Pappas A; Tarca AL; Chaemsaithong P; Dong Z; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2014 Jan; 27(2):132-44. PubMed ID: 23687930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice.
    Oggè G; Romero R; Kusanovic JP; Chaiworapongsa T; Dong Z; Mittal P; Vaisbuch E; Mazaki-Tovi S; Gonzalez JM; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2010 Aug; 23(8):820-7. PubMed ID: 20158394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.
    Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS
    Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences.
    Tsatsaris V; Goffin F; Munaut C; Brichant JF; Pignon MR; Noel A; Schaaps JP; Cabrol D; Frankenne F; Foidart JM
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5555-63. PubMed ID: 14602804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating angiogenic and antiangiogenic factors in women with eclampsia.
    Vaisbuch E; Whitty JE; Hassan SS; Romero R; Kusanovic JP; Cotton DB; Sorokin Y; Karumanchi SA
    Am J Obstet Gynecol; 2011 Feb; 204(2):152.e1-9. PubMed ID: 21062661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia.
    Tripathi R; Rath G; Ralhan R; Saxena S; Salhan S
    Yonsei Med J; 2009 Oct; 50(5):656-66. PubMed ID: 19881969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on p38 mitogen activated protein kinase in vascular endothelial cells dysfunction in preeclampsia].
    Luo X; Liu DD; Qi HB; Yao ZW
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):36-40. PubMed ID: 21429433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.